Correction

Figures & data

Table 2. Clinical outcomes per 100,000 patients over a 3-year time horizon, stratified by treatment received in the DAPA-CKD trial.¹¹

	Event incidence
Outcome	Dapagliflozin plus standard therapy	Standard therapy	Incremental	Number needed to treat
ESKD	7,221	10,767	−3,546	28
HHF	2,370	4,684	−2,314	43
AKI	4,110	5,819	−1,709	58
All-cause mortality	6,383	8,875	−2,492	40

Abbreviations. AKI, Acute kidney injury; ESKD, End-stage kidney disease; HHF, Hospitalization for heart failure.